As of March 31, 2026, Aethlon Medical, Inc. carries a market capitalization of 17.20M, placing it among publicly traded companies globally. Its enterprise value stands at 12.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 17.20M |
| Enterprise Value | 12.51M |
Aethlon Medical, Inc.'s next confirmed earnings release is scheduled for February 15, 2027.
| Earnings Date | 2/15/2027 |
As of March 31, 2026, Aethlon Medical, Inc. has 1.57M shares outstanding.
| Shares Outstanding | 1.57M |
These figures are as of March 31, 2026.
| PB Ratio | 3.52 |
| P/TBV Ratio | 3.52 |
| P/FCF Ratio | -0.23 |
| P/OCF Ratio | -0.23 |
As of March 31, 2026, Aethlon Medical, Inc. maintains a current ratio of 3.85, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.85 |
| Quick Ratio | 3.47 |
| Debt / Equity | 6.89 |
| Debt / EBITDA | -0.05 |
Over the twelve months ended March 31, 2026, Aethlon Medical, Inc. posted a negative return on equity (ROE) of -142.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -104.46, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 9.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | -142.89 |
| Return on Assets (ROA) | -104.46 |
| Employee Count | 9.00 |
As of the close on November 16, 2026, Aethlon Medical, Inc.'s stock has declined approximately 79.76% over the past 52 weeks. The 50-day moving average sits at 5.19, while the 200-day moving average is 7.31.
| 52-Week Price Change | -79.76% |
| 50-Day Moving Average | 5.19 |
| 200-Day Moving Average | 7.31 |
Over the twelve months ended March 31, 2026, Aethlon Medical, Inc. generated - - in revenue and converted that into -7.15M in net income, yielding earnings per share of -47.70. EBITDA reached -6.97M, while operating income came in at -7.29M.
| Operating Income | -7.29M |
| Pretax Income | -7.15M |
| Net Income | -7.15M |
| EBITDA | -6.97M |
| EBIT | -7.29M |
| Earnings Per Share (EPS) | -47.70 |
As of March 31, 2026, Aethlon Medical, Inc. holds 5.03M in cash and equivalents against 336,718.00 in total debt, resulting in a net debt position of -5.03M. Total book value stands at 4.89M, with working capital of 4.12M providing operational flexibility.
| Cash & Cash Equivalents | 5.03M |
| Total Debt | 336,718.00 |
| Net Debt | -5.03M |
| Equity (Book Value) | 4.89M |
| Book Value Per Share | 3.11 |
| Working Capital | 4.12M |
Aethlon Medical, Inc. produced -7.00M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -2,051.00 in capital expenditures, free cash flow totaled -7.00M - equivalent to -46.69 per share.
| Operating Cash Flow | -7.00M |
| Capital Expenditures | -2,051.00 |
| Free Cash Flow | -7.00M |
| FCF Per Share | -46.69 |
These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -426.39: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -37.93, meaning Aethlon Medical, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -37.93 |
| FCF Yield | -426.39 |
Aethlon Medical, Inc.'s most recent stock split took place on August 4, 2026 with a 5:1 split ratio.
| Last Split Date | 8/4/2026 |
| Split Ratio | 5:1 |
As of March 31, 2026, Aethlon Medical, Inc. has an Altman Z-Score of -34.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -34.60 |